Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Sugisaki K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group.
Hirabayashi Y, et al. Among authors: takagi m.
Mod Rheumatol. 2016 Nov;26(6):828-835. doi: 10.3109/14397595.2016.1160991. Epub 2016 Apr 21.
Mod Rheumatol. 2016.
PMID: 26934116